CRISPR Therapeutics Milestone and Market Outlook
CRISPR Therapeutics (NASDAQ: CRSP) is expected to generate approximately $40 million in revenue from its approved gene-editing drug, Casgevy, in 2023, with projections of over $160 million in 2024. As of the first quarter, over 500 patients have begun treatment, though the therapy’s custom nature contributes to a lengthy preparation time of up to a year.
Microsoft (NASDAQ: MSFT) saw its stock drop 25% from last August’s peak, primarily due to concerns over its cloud computing and AI segments. Following a significant restructuring that includes laying off nearly 5,000 employees, analysts have set a 12-month price target of $554.77, suggesting a potential increase of over 40% from the current share price.
Recursion Pharmaceuticals (NASDAQ: RXRX) is positioned for growth, with analysts estimating its value at an average of $7.25 per share, over 100% higher than its current price. The company is advancing several drug development projects, including cancer treatments, and is expected to provide updates on key products later this year or early next year.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
